

# Tocilizumab in Lung Transplantation

NCT06033196

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	National Institute of Allergy and Infectious Diseases (NIAID)
<b>Enrollment</b>	350 participants

## Key Eligibility Criteria

---

### Inclusion (19)

- Study Entry:
  - Subject and/or parent guardian must be able to understand the purpose of the study and willing to participate and sign informed consent/assent
  - Greater than or equal to 30 kg body weight
  - Listed or received for a primary lung transplant
  - No previous or planned desensitization therapy prior to transplant
- ... and 14 more (see full listing online)

### Exclusion (57)

- Study Entry:
  - Listed for multi-organ transplant (e.g., heart-lung, liver-lung, kidney-lung)
  - Prior history of allogeneic organ or cellular transplantation
  - Received treatment to deplete Human Leukocyte Antigens (HLA) antibodies before transplantation
  - Currently breast-feeding a child or plans to become pregnant during the timeframe of the study follow up period
- ... and 52 more (see full listing online)

## Locations (21 total)

---

St. Joseph's Hospital and Medical Center (Site #: 71192), Phoenix, Arizona, United States  
Cedars Sinai Medical Center (Site #: 71146), Beverly Hills, California, United States  
David Geffen School of Medicine at UCLA (Site #: 71123), Los Angeles, California, United States  
... and 18 more locations